RYTM vs WST
Rhythm Pharmaceuticals, Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
RYTM
Rhythm Pharmaceuticals, Inc.
62
Buy
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | RYTM | WST |
|---|
| AI Score |
62
|
74
|
| Price |
$112.61
|
$351.74
|
| P/E Ratio |
-36.28×
|
44.65×
|
| ROE |
-72.8%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.0%
|
36.8%
|
| Debt / Equity |
0.02×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
59.9
|
58.0
|
| Beta |
1.974
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for RYTM versus WST.
WST leads by 12 points.
WST scores 74/100 (Buy) versus RYTM at 62/100 (Buy).
RYTM Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 16.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 16.3% signals elevated volatility — Risk
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical